Clinical trials: High-risk PCI
Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
STRATegy SUccesS in High-Risk PCI With Impella CP: Evaluation of Hemodynamic Protection in Complex PCI
STRATUS-PCI is a pilot clinical trial that compares two ways of running a small heart pump called Impella CP during a high-risk procedure to open blocked heart arteries (percutaneous coronary intervention, or PCI) in patients…
- Trial name
- STRATUS-PCI (NCT07588399)
- Testing
- Impella CP
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Rayyan Hemetsberger
High-Risk Percutaneous Coronary Intervention (High-risk PCI)
ELEVATE High-Risk PCI Pivotal Study
The ELEVATE III Pivotal Study is a prospective, multi-center, open-label, interventional, randomized, controlled study with an active control group.
- Trial name
- ELEVATE III (NCT07001332)
- Testing
- Elevate, Impella
- Where
- 33 sites in United States
- Volunteers
- 290 people
- Sponsor
- Magenta Medical Ltd.
Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease
Studies exploring the feasibility of drug-eluting balloon (DCB) in de-novo coronary lesions are limited. There are scarce data comparing DCB with drug-eluting stent (DES) in patients with high bleeding risk (HBR), a situation in…
- Trial name
- DCB_DES (NCT07442500)
- Testing
- Drug coated balloon, Drug-eluting stent
- Where
- South Korea
- Volunteers
- 470,000 people
- Sponsor
- Samsung Medical Center
Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR)
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype.
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07354828
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Shenyang Northern Hospital
Stable Angina Pectoris, Ad Hoc Percutaneous Coronary Intervention
Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- DOSER (NCT00638326)
- Testing
- clopidogrel
- Where
- Hungary
- Volunteers
- 500 people
- Sponsor
- University of Pecs
Myocardial Infarction
Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction
Rationale: Heart attacks are a major cause of death and result from coronary blood clots that require acute coronary intervention and antithrombotic drugs to restore blood flow and prevent new heart attacks.
- Trial name
- Dan-DAPT (NCT05262803)
- Testing
- CYP2C19*2/*3, Shorter DAPT duration
- Where
- 6 sites in Denmark
- Volunteers
- 2,808 people
- Sponsor
- Rikke Sorensen
High-Risk Percutaneous Coronary Intervention
Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol
The Impella ECP Study is a prospective, multi-center, single-arm study evaluating the rate of major adverse cardiovascular and cerebrovascular events (MACCE) with the Impella ECP device in adult patients undergoing elective or…
- Trial name
- NCT05334784
- Testing
- Impella ECP
- Where
- 32 sites in United States
- Volunteers
- 856 people
- Sponsor
- Abiomed Inc.
High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Interventional Left Ventricular Assist System for PCI in CHIP Patients
Mechanical circulatory support (MCS) is a life-sustaining therapy first introduced in the 1950s. After six decades of development, it now serves as a critical bridge therapy for patients with acute cardiac events and end-stage…
- Trial name
- NCT07053618
- Testing
- Implantation of the VADLINK Percutaneous Left Ventricular Assist Device, VA-ECMO
- Where
- 15 sites in China
- Volunteers
- 286 people
- Sponsor
- Suzhou Hengruihongyuan Medical Technology Co. LTD
High Bolus Dose of Tirofiban
Effect of Upstream High Bolus Dose of Tirofiban in Primary PCI for the Patients With STEMI on Short Term Outcome
The goal of the study to investigate the impact of upstream HBD of Tirofiban on short outcome of STEMI patient.
- Trial name
- TISP (NCT04111289)
- Testing
- -Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)
- Volunteers
- 150 people
- Sponsor
- Assiut University
Acute Coronary Syndrome, Myocardial Infarction
Point of Care (POC) Biomarkers of Ischemia
Acute coronary syndrome is defined as myocardial infarction or ischemia as evidenced by significant coronary artery disease on cardiac catheterization/revascularization or reversible defect seen on stress test.
- Trial name
- NCT02039882
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Acute Coronary Syndrome
High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay
High on-treatment platelet reactivity to adenosine diphosphate was a important reason to cause ischemic events in antiplatelet therapy.
- Trial name
- HOPEmultiPFA (NCT02699008)
- Testing
- Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 477 people
- Sponsor
- Wuhan Asia Heart Hospital
Acute Coronary Syndrome, Type 2 Diabetes
A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
The purpose of this study is to determine the safety and feasibility of BXT-51072 as a cardioprotective agent in diabetics undergoing elective angioplasty / percutaneous intervention (PCI), a procedure to "open" coronary…
- Trial name
- NCT00320502
- Testing
- BXT-51072
- Where
- 4 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Synvista Therapeutics, Inc
Coronary Artery Disease, Heart Failure
Clinical Trial of Ventiflow LP Supporting High-risk Percutaneous Coronary Intervention(PCI)
The purpose of this prospective, multicenter, randomized controlled clinical trial is to evaluate the effectiveness of the transcatheter left ventricular assist system (Ventiflow LP) in providing circulatory support to patients…
- Conditions
- Coronary Artery Disease, Heart Failure, High-risk PCI
- Trial name
- NCT06754839
- Testing
- Percutaneous left ventricular assist device(Ventiflow LP), VA-ECMO
- Volunteers
- 250 people
- Sponsor
- Suzhou Hearthill Medical Technology Co.,LTD
Coronary Artery Disease
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI
To determine the safety and efficacy of Ticagrelor versus Clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary…
- Trial name
- PL-PLATELET (NCT03078465)
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Coronary Artery Disease
Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI)
Thrombotic event is one of the most serious complications of coronary artery disease, which often result in myocardial infarction and even death.
- Trial name
- spirit (NCT01371058)
- Testing
- high maintenance clopidogrel, routine dual antiplatelet, policosanol plus dual antiplatelet
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shenyang Northern Hospital
High-Risk Percutaneous Coronary Intervention
Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients
The Elevate™ First-In-Human (FIH) study is designed to evaluate the initial safety and device functionality of the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk…
- Trial name
- ELEVATE I (NCT06099548)
- Testing
- The Elevate™ System
- Where
- 2 sites in Georgia
- Volunteers
- 20 people
- Sponsor
- Magenta Medical Ltd.
Chronic Total Occlusion of Coronary Artery, Angina Pectoris
Invest-CTO PCI Trial
Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Angina Pectoris, Quality of Life, PROM
- Trial name
- NCT04774913
- Testing
- Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)
- Where
- 5 sites in United States, Norway and 1 more
- Volunteers
- 200 people
- Sponsor
- Haukeland University Hospital
Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01109784
- Testing
- prasugrel, clopidogrel
- Where
- Greece
- Volunteers
- 70 people
- Sponsor
- University of Patras
Myocardial Infarction, Statin Adverse Reaction
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg.
- Conditions
- Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
- Trial name
- ROSUZET-AMI (NCT04499859)
- Testing
- Ezetimibe 10mg + Rosuvastatin 5mg, Rosuvastatin 20mg
- Where
- 7 sites in South Korea
- Volunteers
- 3,548 people
- Sponsor
- Kiyuk Chang, MD,PhD
Coronary Artery Disease, DES
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
We hypothesized that clopidogrel mono-therapy will not be inferior to the extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or patients at high risk for either ischemic or bleeding…
- Trial name
- NCT03947229
- Testing
- Clopidogrel mono-therapy, Dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,200 people
- Sponsor
- Yonsei University